Back to search results

Understanding Lipoprotein Kinetics in Type 1 Diabetes

This study aims to understand why people with Type 1 Diabetes (T1D) have a higher risk of heart disease and stroke. Researchers will compare how fats (lipoproteins) are processed in people with T1D and healthy individuals. You might be able to join if you are between 18 and 45 years old, not pregnant or breastfeeding, and have a healthy weight (BMI between 18.5 and 30). For healthy participants, additional blood sugar requirements apply. The study will measure the turnover rate of a specific protein called Apolipoprotein C to see how it differs. The current status of this study is unclear, and it plans to enroll 30 participants.

Study design
This is an interventional study planning to enroll 30 participants. It is a cross-sectional, observational study.
What's involved
Participants will complete a metabolic testing protocol, which includes intravenous infusions of stable isotope labeled tracers and blood sampling.
Compensation
Not stated in the trial record.
Follow-up
Apolipoprotein C turnover rate will be measured at one time, at baseline.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05179954

Lipoprotein Kinetics in T1D

Recruiting
NAAges 18–45InterventionalBasic science
University of Missouri-Columbia
~30 participants
Updated 2026-02-10 on ClinicalTrials.gov
What's tested:Metabolic testing

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Apolipoprotein C turnover rate
Measured over one time, at baseline (this is a cross-sectional, observational study, no intervention)

Conditions

Type 1 Diabetes

Explore related trials

Type 1 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Bettina Mittendorfer · PRINCIPAL_INVESTIGATOR · University of Missouri-Columbia

Who to contact

Amanda Heider
[email protected]
(573) 884-6852
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age: ≥18 but ≤45 years
premenopausal/eumenorrheic and not pregnant or breastfeeding
non-obese (body mass index ≥18.5\<30.0 kg/m2)
Fasting plasma triglyceride \<150 mg/dL
Fasting plasma glucose \<100 mg/dL
Plasma glucose 2 h after a 75 g oral glucose challenge \<140 mg/dL
HbA1c \<5.6%.
stable insulin regimen (multiple daily insulin injections or continuous subcutaneous insulin) for at least 8 weeks before screening
no use of diabetes medications other than insulin
HbA1c \<8.0%, basal (overnight fasted)
no severe symptomatic hypoglycemic event associated with a seizure or requiring help from other people or a medical facility in the 6 months prior to screening or metabolic testing

Exclusion

more than 1.5 h of structured exercise/week
use of tobacco products, excessive amounts of alcohol, or dietary supplements and/or medications known to affect lipid metabolism
hypothyroidism or other disorders known to affect lipid metabolism
conditions that would make it impossible to complete the study protocol

What this trial measures

  • Apolipoprotein C turnover rateone time, at baseline (this is a cross-sectional, observational study, no intervention)

    Apolipoprotein C turnover rate will be assessed by using an intravenous stable isotope labeled amino acid infusion